Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy

Area of Science:

• Immunology
• Neurology
• Biochemistry

Background:

• The complement system is crucial in myasthenia gravis (MG) pathogenesis.
• Anti-complement therapies show promise for anti-acetylcholine receptor (AChR) antibody-positive MG, but high costs limit use.
• Identifying biomarkers for complement activation can guide therapy selection.

Purpose of the Study:

• To identify plasma complement proteins as indicators of complement activation in AChR-MG.
• To explore potential biomarkers for tailoring anti-complement therapy in MG.
• To differentiate complement activation patterns between AChR-MG and MuSK-MG.

Main Methods:

• Plasma samples from AChR-MG, MuSK-MG patients, and healthy controls were analyzed.
• Multiplex immunoassays and ELISA quantified complement components and activation products.
• Classical, alternative, and lectin complement pathways were assessed.

Main Results:

• AChR-MG patients showed reduced C2 and C5 levels, and increased C3, C3b, and C5a compared to controls.
• This protein profile indicated significant complement activation in AChR-MG.
• MuSK-MG patients did not exhibit the same complement activation pattern.

Conclusions:

• A specific plasma complement profile (C2, C3, C5, C3b, C5a) is associated with AChR-MG.
• These complement components show potential as biomarkers for AChR-MG diagnosis and complement activation status.
• Findings offer new avenues for personalized anti-complement therapy in MG.